Identifying molecular markers that predict relapse after therapy discontinuation inchronic myeloid leukemia.
Elizabeth A. Eklund
Congressional District Code:
Clinical Science R&D
April 2019 -
FY 2021 Funding Amount:
Total Award Amount (all years):
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt:
Clinical outcomes in chronic myeloid leukemia (CML) were revolutionized by development of imatinib (IM) and later generation tyrosine kinase inhibitors (TKIs) that target the Bcr-abl oncogene. Currently, ~55% patients with newly diagnosed CML achieve a major molecular response to TKI treatment (MMR) and 17% a complete molecular response (CMR). Because CML patients survive many years, there is interest in identifying those who can discontinue treatment. This interest is encouraged by the 30% inci...